Docoh
Loading...

77 results

Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, or other notice or action relating to the alleged lack … of safety or efficacy of any product or any alleged product defect or violation and, to the Company’s knowledge, no third party has initiated
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 Aug 21
Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
6:16am
evaluating the safety and PK of PCS6422 and capecitabine when administered to patients with advanced, refractory GI cancer. The combination of PCS6422 … and capecitabine is expected to improve the benefit-risk profile of capecitabine by improving capecitabine safety and/or efficacy. Licensed in PCS3117
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
became effective, such that we initiated and completed a Phase 2A multicenter, open-label prospective trial designed to determine the safety … visit took place in February 2020. The primary objective of the Phase 2A trial was to evaluate the safety and tolerability of PCS499 in patients with NL
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
, taking into account actual and potential issues of safety, efficacy or stability, product profile (including product modality, category and mechanism … a Clinical Trial of a compound or product for an Indication, the principal purpose of which is a determination of safety and efficacy for such Indication
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
and Safety of PCS499 in Treating Ulcerations in Patients who Have Necrobiosis Lipoidica.” In order to expedite enrollment for this rare condition, we … “A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors.” We have received guidance
10-Q
645qj 5mgbysjbafp1
13 May 21
Quarterly report
4:30pm
DEF 14A
722cjjd01ng chtqpc
22 Apr 21
Definitive proxy
2:00pm
10-K/A
a4nkf4
7 Apr 21
Annual report (amended)
4:23pm
10-K
1vxjkpr86 m2h5e1lcge
24 Mar 21
Annual report
8:00pm
8-K
EX-99.1
fuql57x9jqtx7o
24 Mar 21
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
8:00pm
8-K
EX-10.1
l8dse9 2jldpqofrk8s
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
10-Q
3oh8hml5y0 t3cxa
12 Nov 20
Quarterly report
4:01pm
8-K
EX-1.1
8r8gijx8qty pfdk60
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
s9nuw0lmoxasg31
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
xyju2 kvll
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
bf22bze6ukbi
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-2.1
41s9j v226108
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-1.1
2tvnd
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-3.2
mjx294zwprnm82xjwt
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.13
xn3p1bbc jouuh
16 Sep 20
IPO registration (amended)
8:00pm